Short answer
PTCH1 genetic testing is most useful when Gorlin syndrome, also called nevoid basal cell carcinoma syndrome or basal cell nevus syndrome, is already suggested by the pattern. Clues include multiple early basal cell carcinomas, jaw keratocysts, palmar or plantar pits, falx calcification, skeletal anomalies, and a family history that fits. PTCH1 is the most common gene, but SUFU matters too, especially when the family history includes early childhood medulloblastoma.
What testing can clarify
| Situation | Testing question | Why it matters |
|---|---|---|
| Multiple young-onset BCCs or jaw cysts | Does PTCH1 confirm Gorlin syndrome? | A molecular result can support the diagnosis and guide follow-up. |
| Known family variant | Should relatives have targeted testing? | Targeted testing is clearer than broad guessing. |
| Early childhood brain tumor in the family | Should SUFU be added? | SUFU can change brain-surveillance timing and risk counseling. |
| Clinically suspicious but negative blood test | Could mosaicism or a broader panel matter? | A negative blood test does not always end the question. |
When testing helps
- When skin, jaw, or skull findings already point toward Gorlin syndrome.
- When a family member has a known PTCH1 or SUFU pathogenic variant and relatives need cascade testing.
- When the result will affect skin surveillance, dental imaging, brain screening, or radiation planning.
- When a child has medulloblastoma or the family history suggests a higher childhood brain-tumor risk.
When a negative result does not settle the diagnosis
- PTCH1 is common, but not every Gorlin syndrome case is PTCH1.
- Some families have SUFU or other less common findings that a narrow test may miss.
- Mosaicism can make blood testing negative even when the phenotype is real.
- If the clinical pattern is strong, the diagnosis may still stand and the panel may need to be broadened.
Why surveillance matters
| Area | Typical follow-up after diagnosis |
|---|---|
| Skin | Regular dermatology exams and strict sun protection because basal cell carcinomas can recur over time. |
| Jaw and teeth | Dental or oral-maxillofacial follow-up with panoramic imaging for keratocysts. |
| Brain | Early childhood neurologic review is especially important when SUFU is involved because medulloblastoma risk is higher. |
| Other organs | Age- and sex-specific follow-up may include ophthalmology, gynecology, and other specialty care depending on the phenotype. |
What follow-up may include
Follow-up for Gorlin syndrome often includes dermatology review, jaw and dental surveillance, imaging plans when needed, and family testing if the result is inherited. The exact surveillance pattern depends on the variant, age, and prior findings.
Questions to ask
- Was PTCH1 tested alone or in a panel that also included SUFU and deletion/duplication analysis?
- Does the result fit the clinical diagnostic criteria or only part of them?
- Should relatives have targeted testing, skin exams, dental imaging, or neurologic surveillance?
- Is radiation avoidance part of the care plan if Gorlin syndrome is confirmed?
- What follow-up changes if the result is a VUS instead of pathogenic?
FAQ
- What genes are usually tested for Gorlin syndrome?
- PTCH1 is the main gene, but SUFU is also important and may be especially relevant when early medulloblastoma is part of the family story.
- Does a negative PTCH1 result rule out Gorlin syndrome?
- No. A negative PTCH1 result does not fully rule it out if the clinical pattern is strong, because some cases involve SUFU, mosaicism, or a broader genetic explanation.
- Why does SUFU matter?
- SUFU changes childhood brain-tumor risk and therefore changes how early and how often surveillance may start.
- What screening may follow a positive result?
- Dermatology, dental imaging, sun protection, and age-specific neurologic or other specialty follow-up may be considered.
- Should children or siblings be tested?
- If a pathogenic family variant is known, targeted cascade testing can identify relatives who need earlier surveillance.
- Is Gorlin syndrome just a skin cancer problem?
- No. Skin cancers are a major part of the picture, but jaw cysts, skeletal findings, and childhood brain-tumor risk can also matter.
Bottom line: PTCH1 testing is most useful when the skin, jaw, family, and childhood-tumor clues point toward Gorlin syndrome and the result will change surveillance.